Seizure freedom · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants seizure‐free at 24 months after randomization ‐ not reported · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion free from seizures (Engel Class 1) at 2 years · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants' assessment of improvement of pain in right TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in right TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of right masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of right masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Jaw pain (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in jaw pain (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Participants' assessment of improvement of pain in left TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in left TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of left masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of left masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
2 findings from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: dry mouth compared with placebo (very low certainty).
1 finding from 1 review